



ASX / Media Release
6 July 2016

48th European Pancreatic Club meeting

Sydney, Australia, 6 July 2016: OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, today announced that a team of senior management would be attending the 48th *European Pancreatic Club (EPC)* meeting in Liverpool, England.

The *European Pancreatic Club* meeting hosted by EPC President, Professor John Neoptolemos is focused entirely on pancreatic diseases and pancreatic cancer, making it one of the key international Scientific meetings for the Company to attend. This year the EPC meeting will run from 6 to 9 July 2016 and will host over 80 invited speakers from across Europe, the United States, Asia and Australia.

The Company's recently appointed Sales and Marketing Director, Michael Warrener and Chief Medical officer, Dr Ash Soman will be attending to discuss and introduce the OncoSil™ technology to a number of leading pancreatic cancer clinicians. A key focus will be to identify additional key opinion leaders and potential commercial and clinical sites for OncoSil™ as the Company prepares for the planned CE Mark and IDE regulatory decisions.

The Company's Sales and Marketing Director, Michael Warrener said:

"The EPC meeting is a key meeting for OncoSil Medical and our team plans to introduce our technology to the clinicians who we hope will become key opinion leaders and prescribers of OncoSil™ for their patients, many of whom have unresectable pancreatic cancer and poor survival prospects. We already have a busy schedule of meetings with leading clinicians across a range of high volume centres in the United Kingdom and have been pleased with their willingness to meet and become better acquainted with our device.

As we move forward into commercialisation in the EU, as planned later this year, broader clinical and society support is a key goal for us to drive adoption, revenues and ultimately reimbursement."

Details on the EPC meeting and presentations can be found at www.epc2016.org.

ENDS

Company	Investor Enquiries	Media
Mr Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au T: +61 2 9223 3344	David Allen or John Granger Hawkesbury Partners E: dallen@hawkesburypartners.com T: +61 2 9325 9046	James Moses Mandate Corporate E: james@mandatecorporate.com.au M: +61 420 991 574

About OncoSil™

OncoSil™ is a clinical-stage medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical trials with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch planned for 2H2016, subject to approval.

An Investigational Device Exemption has also been lodged with the U.S Food and Drug Administration to seek approval to conduct a global clinical study of the OncoSil™ device. The aim of the study will be to collect safety and effectiveness data required to support a Premarket Approval (PMA) application. .

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.